LOS ALTOS, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or ...
- Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Unicycive Therapeutics ( (UNCY)) just ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA rejected the company's ...
Fintel reports that on October 29, 2025, HC Wainwright & Co. maintained coverage of Unicycive Therapeutics (NasdaqCM:UNCY) with a Buy recommendation. As of October 29, 2025, the average one-year price ...
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...
LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for ...
LOS ALTOS, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results